Copyright © Inderes 2011 - present. All rights reserved.

Happy Helper

Less than 1K followers
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Johnson & Johnson had a good third quarter; revenue and earnings exceeded expectations, and the company also raised its outlook for this year. Both the pharmaceutical side and medical devices grew strongly, and earnings also clearly improved from last year. The company plans to spin...
10/14/2025, 8:46 PM
by Sijoittaja-alokas
10
Johnson & Johnson says it has reached an agreement with the Trump administration to lower drug prices for Americans. In exchange, the company will receive an exemption from U.S. tariffs on pharmaceuticals. J&J plans to participate in the TrumpRx.gov program and promise “more comparable...
1/9/2026, 6:39 AM
by Sijoittaja-alokas
6
The company’s “final quarter” beat expectations in terms of both earnings and revenue. The overall performance looked quite okay, nothing too surprising – at the time of writing, it’s down 3.5% in the pre-market, but let’s see what happens when the market opens. Growth was driven...
1/21/2026, 1:19 PM
by Sijoittaja-alokas
4
Johnson & Johnson now faces over 73,000 lawsuits, as its talcum powder is alleged to cause cancer. The company’s settlement attempt was rejected, the product was removed from the market, but J&J nevertheless denies the allegations and caps potential compensation at $9 billion. Johnson...
10/27/2025, 7:52 PM
by Sijoittaja-alokas
4
A Los Angeles jury ordered Johnson & Johnson to pay $966 million to the family of a woman who died of mesothelioma, as the court found that the company’s talc products contained asbestos and caused cancer. J&J denies the allegations and plans to appeal; additionally, the company ...
10/7/2025, 11:47 PM
by Sijoittaja-alokas
4
According to the article below, Johnson & Johnson is planning to sell its DePuy Synthes unit, which specializes in orthopedic surgery. The value of the deal is expected to exceed $20 billion. According to the article, private equity firms and industry competitors have shown interest...
2/19/2026, 9:40 PM
by Sijoittaja-alokas
3
Johnson & Johnson acquired Halda Therapeutics for $3.05 billion and gained a cancer drug platform as well as a prostate cancer drug candidate. Returns may come later (or maybe not :D), but in the coming years, the deal will weigh on earnings according to the article. The acquisition...
12/30/2025, 10:08 PM
by Sijoittaja-alokas
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.